Pacer Advisors Inc. grew its stake in Novartis AG (NYSE:NVS) by 6.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,512 shares of the company’s stock after purchasing an additional 1,482 shares during the period. Pacer Advisors Inc.’s holdings in Novartis AG were worth $2,019,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. City Holding Co. grew its position in shares of Novartis AG by 4.6% in the second quarter. City Holding Co. now owns 1,217 shares of the company’s stock valued at $102,000 after purchasing an additional 54 shares in the last quarter. WFG Advisors LP grew its position in shares of Novartis AG by 38.1% in the second quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock valued at $102,000 after purchasing an additional 337 shares in the last quarter. Cable Hill Partners LLC grew its position in shares of Novartis AG by 588.8% in the third quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock valued at $112,000 after purchasing an additional 1,107 shares in the last quarter. Archford Capital Strategies LLC grew its position in shares of Novartis AG by 72.3% in the first quarter. Archford Capital Strategies LLC now owns 1,480 shares of the company’s stock valued at $110,000 after purchasing an additional 621 shares in the last quarter. Finally, North Star Investment Management Corp. grew its position in shares of Novartis AG by 1.0% in the second quarter. North Star Investment Management Corp. now owns 1,542 shares of the company’s stock valued at $129,000 after purchasing an additional 16 shares in the last quarter. Institutional investors and hedge funds own 10.74% of the company’s stock.

Several research analysts recently weighed in on NVS shares. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Novartis AG in a research report on Tuesday, September 5th. Zacks Investment Research upgraded Novartis AG from a “sell” rating to a “hold” rating in a research report on Thursday, October 26th. Leerink Swann increased their price objective on Novartis AG from $89.00 to $91.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. BidaskClub upgraded Novartis AG from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. Finally, Cowen and Company set a $90.00 price objective on Novartis AG and gave the stock a “hold” rating in a research report on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and four have issued a buy rating to the company. Novartis AG has a consensus rating of “Hold” and an average target price of $85.32.

ILLEGAL ACTIVITY NOTICE: “Pacer Advisors Inc. Has $2.02 Million Stake in Novartis AG (NVS)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/20/pacer-advisors-inc-has-2-02-million-stake-in-novartis-ag-nvs.html.

Shares of Novartis AG (NVS) traded up $0.96 during midday trading on Monday, hitting $83.98. The stock had a trading volume of 1,545,600 shares, compared to its average volume of 2,323,214. The firm has a market capitalization of $198,662.67, a PE ratio of 17.68, a P/E/G ratio of 2.68 and a beta of 0.72. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. Novartis AG has a twelve month low of $66.93 and a twelve month high of $86.90.

Novartis AG (NYSE:NVS) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.04. The business had revenue of $12.41 billion for the quarter, compared to analysts’ expectations of $12.21 billion. Novartis AG had a return on equity of 15.77% and a net margin of 13.73%. The company’s revenue for the quarter was up 2.4% compared to the same quarter last year. During the same period last year, the firm earned $1.23 earnings per share. sell-side analysts expect that Novartis AG will post 4.75 earnings per share for the current fiscal year.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Institutional Ownership by Quarter for Novartis AG (NYSE:NVS)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.